INTRODUCTION
============

In recent years, prognosis of human immunodeficiency virus type 1 (HIV-1) infection has been markedly improved by combinational antiretroviral therapy (cART). It is no exaggeration to say that adherence to cART is the most important critical factor to determine success/failure of this therapy. The cART regimen recommended for initial treatment includes two nucleoside reverse transcriptase inhibitors (NRTIs) as the backbone, in combination with a single non-NRTI (NNRTI) or a protease inhibitor or an integrase inhibitor.[@b1]--[@b4]

Epizicom is a fixed-dose combination tablet developed by GlaxoSmithKline, containing 300 mg of lamivudine and 600 mg of abacavir, for the purpose of improving adherence to drug intake and enabling once-daily oral administration of the backbone (one tablet/dose). The combination of abacavir +lamivudine has been used in many overseas clinical studies to show its effectiveness against HIV infection,[@b5]--[@b10] and it is listed as a favourable NRTI backbone combination in international and local HIV treatment guidelines as of 2012.[@b2]--[@b4] Because this combined drug was approved in the USA in August 2004 and in Europe in December 2004, it has been approved in more than 40 countries by March 2011. In Japan, it was marketed in January 2005. The application for approval of Epzicom in Japan was subjected to preferential review as anti-HIV drug, and its review by the regulatory authority was made quickly on the basis of overseas data. Its components abacavir (Ziagen®) and lamivudine (Epivir®) have been marketed in Japan since 1999 and 1997, respectively. Thus, there had already been much clinical experience as to the safety and efficacy of long-term use of the components of Epzicom in Japan by the time of submission. However, no domestic clinical data on the combined form were available before approval of the product. Thus, the approval for this product in Japan was made with a condition that the marketing authorization holder collects information on clinical use of this product within the framework of post-marketing surveillance. In response to this special requirement, post-marketing data on clinical use of Epzicom were collected from 624 cases managed at 27 domestic facilities between January 2005 and December 2010. We here report safety and effectiveness data on this product obtained from the post-marketing surveillance. The safety data presented here is based on those officially reported to the Japanese regulatory authority (Pharmaceuticals and Medical Devices Agency \[PMDA\]) on 22 March 2011.

METHODS
=======

Subjects
--------

In Japan, anti-HIV drugs are designated orphan drugs (medicines used for rare diseases). Because the number of HIV + people is small in Japan and anti-HIV drugs are commonly used with other drugs for treatment of HIV infection (anti-HIV drugs, drugs for treatment of opportunistic infection and so on), a joint survey (HIV-related drug \[HRD\] surveys) has been conducted, involving manufacturers and distributors of drugs for treatment of HIV infection. The survey has been conducted at registered sites, designed to collect safety and effectiveness information on antiretrovirals marketed in Japan. It was designed to enrol all of the patients receiving antiretrovirals in principle; however, the decisions of the enrollment were made by contractor physicians; a common survey form has been filled out by the contractor physicians and recollected in each year. The management of the survey has been delegated to Nihon Ultmarc Inc. (currently CMIC-PMS Co., Ltd.). The post-marketing survey on Epzicom covered all Epzicom-treated patients registered to the HRD survey between January 2005 and March 2009 (final follow-up in December 2010). Note that the safety data presented here are based on those officially reported to the PMDA on 22 March 2011 after the completion of mandatory post-marketing surveillance for this drug. In addition, a survey on safety of Epzicom use during pregnancy was conducted if such cases were experienced.

Observed items for safety analysis
----------------------------------

Information was collected as to the reason (disease name) for use of the product; gender; age; race; history of anti-HIV drug treatment; complications upon registration (including renal dysfunction, hepatic dysfunction, and haemophilia); concomitant drugs; CDC disease stage[@b11] situations of product use (dosing method, dose level, dosing period); situation of concomitant drug use; presence/absence of adverse events (AEs) developing after the start of Epzicom treatment; and name of AEs and their date of onset, course, intervention and seriousness (events causing death, disabilities, hospitalization, semi-serious outcome, congenital anomalies, etc., listed in Item 253 of the Pharmaceutical Affairs Law Enforcement Rules were deemed as serious). The causal relationship of each AE to the product was rated on a five-category scale 'definitely associated', 'associated', 'not ruled out', 'unknown' or 'ruled out'. The AEs except 'ruled out' were defined as 'adverse drug reactions (ADR)' in the present analysis. Terminology of AEs in this report strictly follows MedDRA version 13.1. In addition, the following were investigated as topics of special focus: (1) hypersensitivity reaction (criteria for hypersensitivity given in Table [1](#tbl1){ref-type="table"}); (2) association with pre-existing hepatic dysfunction; and (3) Epzicom use in pregnant women.

###### 

Criteria for hypersensitivity[†](#tf1-1){ref-type="table-fn"}

  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category A           Hypersensitivity/anaphylactic symptoms/allergic reactions/drug allergy
  Category B           Cases meeting the following two or more items:
                       • Rash
                       • Fever
                       • Gastrointestinal symptoms (nausea, vomiting, diarrhoea and abdominal pain)
                       • Constitutional symptoms (coma, fatigue, malaise, myalgia and abnormal chest radiographs \[infiltration is mainly noted and may be localized in some cases\])
  Exclusion criteria   • A patient in whom other causes are highly probable despite the presence of hypersensitivity-like symptoms
                       • A patient without recurrence after readministration of abacavir
                       • A patient with disappearance of symptoms during treatment with abacavir
                       • A patient who does not meet the criteria for category B despite suspected hypersensitivity to abacavir
  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients who meet the criteria for category A or B but not the exclusion criteria are determined to have hypersensitivity to abacavir.

Effectiveness analysis
----------------------

To investigate effectiveness of the drug, surrogate markers (plasma HIV-RNA copy number and CD4 +T-cell count) were measured before and after starting Epzicom treatment; however, this analysis was limited to the patients who had never received prior antiretroviral treatment.

Statistical analysis
--------------------

Background variables of patients were subjected to stratified analysis and so on, using chi-square test or Fisher\'s exact test, and *p* \< 0.05 (two-tailed) was regarded statistically significant. For multivariate analysis, logistic regression analysis was performed with stepwise selection. All of the statistical analyses were conducted using SAS Ver 9.13.

RESULTS
=======

Background characteristics of the surveyed patients
---------------------------------------------------

The survey form was recollected from all of the 624 patients treated with Epzicom among the patients registered to this survey from nationwide 27 facilities participating in the joint HRD survey. Analysis of safety was conducted on 1107.3 person-years, and 126 of 624 were lost during the observed period. Table [2](#tbl2){ref-type="table"} summarizes the background characteristics of the patients. Of the 624 patients surveyed, 94.4% (589 cases) were Japanese, with the percentage of men being 92.8% (579 cases). Age ranged from 10 to 81 years, with the percentage of adults (15 ≤ and ≤ 64 years) being 96.0% (599 cases) and the percentage of elderly patients (over 65 years) being 3.7% (23 cases). The reason for use of this product was HIV infection in all cases, with the mean daily dose level being one tablet in all cases. The number of anti-HIV drugs concomitantly used was one in 45.5% (284 cases) and two in 42.1% (263 cases). Thus, all cases were treated with two or more drugs, including Epzicom, implying that all patients were treated with three or more anti-HIV agents. The percentage of patients without a history of other anti-HIV drug therapy before the start of Epzicom therapy (treatment-naïve) was 34.1% (213/624).

###### 

Characteristics of the subjects

                                                                                         Safety analysis population   
  ---------------------------------------------------------------------- --------------- ---------------------------- -------
  Total                                                                  624             100.0                        
  Reason for use                                                         HIV infection   624                          100.0
  Sex                                                                    Male            579                          92.8
                                                                         Female          45                           7.2
  Age[†](#tf2-1){ref-type="table-fn"}                                    15--64 years    599                          96.0
                                                                         65--81 years    23                           3.7
  Ethnic groups                                                          Japanese        589                          94.4
                                                                         Others          35                           5.6
  History of treatment with antiretrovirals                              Absent          213                          34.1
                                                                         Present         411                          65.9
  History of allergy                                                     Absent          322                          51.6
                                                                         Present         210                          33.7
                                                                         Unknown         92                           14.7
  Complications                                                          Absent          158                          25.3
                                                                         Present         466                          74.7
  Renal impairment                                                       Absent          586                          93.9
                                                                         Present         38                           6.1
  Hepatic disorder                                                       Absent          461                          73.9
                                                                         Present         163                          26.1
  Haemophilia                                                            Absent          584                          93.6
                                                                         Present         40                           6.4
  Concomitant use of non anti-HIV drugs                                  Absent          0                            0.0
                                                                         Present         624                          100.0
  Number of concomitant anti-HIV drugs[‡](#tf2-2){ref-type="table-fn"}   None            0                            0.0
                                                                         1 drug          284                          45.5
                                                                         2 drugs         263                          42.1
                                                                         3 drugs         62                           9.9
                                                                         ≥4 drugs        15                           2.4
  CDC classification                                                     A               240                          38.5
                                                                         B               34                           5.4
                                                                         C               121                          19.4
                                                                         Unknown         228                          36.5
  Total duration of treatment (days)                                     2--180          623                          99.8
                                                                         181--365        529                          84.8
                                                                         366--730        444                          71.2
                                                                         731--1517       234                          37.5

Two pts were \<15 years old.

Total numbers throughout the observed periods.

Data on adverse drug reactions
------------------------------

In this survey, ADRs were defined as AEs whose causal relationship to the product could not be 'ruled out'. As shown in Table [3](#tbl3){ref-type="table"}, 202 of the 624 patients showed a total of 325 ADRs, with the incidence being 32.4% (202/624). In addition, ADRs whose causal relationship to the product was rated as 'definitely associated' or 'associated' were seen in 58 patients (9.0%, 101 events). In analysis of the incidence of ADR by MedDRA system organ class, the incidence was the highest with 'metabolism and nutrition disorders' (13.9%, 87/624 patients), followed by 'investigations (laboratory abnormality)' (10.3%, 64/624), 'gastrointestinal disorders' (4.3%, 27/624), 'skin and subcutaneous tissue disorders' (4.0%, 25/624), 'hepatobiliary disorders' (3.7%, 23/624), 'psychiatric disorders' (1.3%, 8/624) and 'nervous system disorders' (1.3%, 8/624). Regarding the names of ADR, the expressions used by the reporting physicians were converted into MedDRA preferred terms, thereby separately processing the ADRs of different expressions used by reporting physicians even if they looked similar (e.g. abnormal hepatic function vs liver disorder, and rash vs drug eruption). When analysed in this way, the number of reported cases was the largest with hyperlipidaemia (59 cases), followed by hypertriglyceridaemia (21 cases), blood bilirubin increased (19 cases), gamma-glutamyltransferase increase (14 cases), blood triglyceride increase (14 cases), rash (14 cases), hyperuricaemia (eight cases), hyperbilirubinaemia (eight cases), blood uric acid increase (eight cases), hepatic dysfunction (seven cases), liver disorder (seven cases), nausea (seven cases), drug eruption (five cases), hypertension (five cases), diabetes mellitus (five cases), diarrhoea (five cases) and so on. Serious AEs were reported on 19 patients (30 events), including two cases each of pancreatitis acute, fever, liver disorder and drug eruption, and one case each of other serious AEs. Of these serious AEs, two events seen in two patients were reported as 'associated' with Epzicom (hepatic dysfunction and immune reconstitution inflammatory syndrome). There was one fatal case (pancytopenia), and the causal relationship to Epzicom was reported as 'not ruled out'; this patient had syphilis, esophageal candidiasis and HIV encephalopathy as underlying diseases, and presented with bone marrow suppression under Valgancyclovir and AZT/3TC prior to starting Epzicom.

###### 

Adverse drug reactions observed during the treatment with Epzicom[†](#tf3-1){ref-type="table-fn"} (325 events in 202 subjects)

  Adverse drug reaction                                                           Cases (%)
  ------------------------------------------------------------------------------- ------------------------
  **Blood and lymphatic system disorders**                                        **4** (**0**.**64**)
  Iron deficiency anaemia                                                         1
  Normochromic normocytic anaemia                                                 1
  Pancytopenia                                                                    1
  Haemorrhagic diathesis                                                          1
  **Cardiac disorders**                                                           **3 (0.48)**
  Atrioventricular block complete                                                 1
  Atrioventricular block first degree                                             1
  Cardiac failure                                                                 1
  **Endocrine disorders**                                                         **1 (0.16)**
  Hyperthyroidism                                                                 1
  **Gastrointestinal disorders**                                                  **27 (4.33)**
  Abdominal discomfort                                                            2
  Abdominal pain                                                                  1
  Abdominal pain upper                                                            2
  Ascites                                                                         1
  Constipation                                                                    1
  Diarrhoea                                                                       5
  Gastritis                                                                       2
  Gingivitis                                                                      1
  Nausea                                                                          7
  Pancreatitis acute                                                              2
  Reflux oesophagitis                                                             2
  Vomiting                                                                        1
  Abdominal symptom                                                               1
  **General disorders and administration site conditions**                        **7** (**1**.**12)**
  Asthenia                                                                        1
  Malaise                                                                         3
  Pyrexia                                                                         3
  **Hepatobiliary disorders**                                                     **23 (3.69)**
  Cholelithiasis                                                                  1
  Hepatic function abnormal                                                       7
  Hepatitis fulminant                                                             1
  Hyperbilirubinaemia                                                             8
  Jaundice                                                                        1
  Liver disorder                                                                  7
  **Immune system disorders**                                                     **1 (0.16)**
  Immune reconstitution symdrome                                                  1
  **Infections and infestations**                                                 **6 (0.96)**
  Hepatitis C                                                                     2
  Herpes zoster                                                                   3
  Influenza                                                                       1
  Atypical mycobacterial infection                                                1
  **Injury, poisoning, and procedural complications**                             **2 (0.32)**
  Spinal compression fracture                                                     1
  Lumbar vertebral fracture                                                       1
  **Investigations**                                                              **65** (**10**.**42**)
  Alanine aminotransferase increased                                              2
  Aspartate aminotransferase increased                                            2
  Blood bilirubin increased                                                       19
  Blood cholesterol increased                                                     3
  Blood creatine phosphokinase increased                                          1
  Blood creatinine increased                                                      1
  Blood glucose increased                                                         1
  Blood lactate dehydrogenase increased                                           1
  Blood triglycerides increased                                                   14
  Blood uric acid increased                                                       8
  Gamma-glutamyltransferase increased                                             14
  Glucose urine present                                                           1
  Blood urine present                                                             1
  Haemoglobin decreased                                                           1
  Liver function test abnormal                                                    3
  Low density lipoprotein increased                                               1
  Platelet count decreased                                                        4
  Lymphocyte count increased                                                      1
  Neutrophil count decreased                                                      1
  White blood cell count decreased                                                1
  Blood alkaline phosphatase increased                                            4
  **Metabolism and nutrition disorders**                                          **87 (13.94)**
  Diabetes mellitus                                                               5
  Glucose tolerance impaired                                                      1
  Gout                                                                            1
  Hypercalcaemia                                                                  1
  Hypercholesterolaemia                                                           3
  Hypertriglycaeridaemia                                                          21
  Hyperuricaemia                                                                  8
  Metabolic disorder                                                              1
  Hyperphosphatasaemia                                                            1
  Decreased appetite                                                              1
  Hyperlipidaemia                                                                 59
  **Musculoskeletal and connective tissue disorders**                             **3 (0.48)**
  Myalgia                                                                         1
  Osteonecrosis                                                                   1
  Osteoporosis                                                                    1
  **Neoplasms benign, malignant, and unspecified (including cysts and polyps)**   **2 (0.32)**
  Kaposi\'s sarcoma                                                               1
  Castleman\'s disease                                                            1
  Metastatic gastric cancer                                                       1
  **Nervous system disorders**                                                    **8 (1.28)**
  Cerebral infarction                                                             1
  Disturbance in attention                                                        1
  Dizziness                                                                       2
  Dysgeusia                                                                       1
  Headache                                                                        2
  Tremor                                                                          1
  **Psychiatric disorders**                                                       **8 (1.28)**
  Depressed mood                                                                  1
  Depression                                                                      3
  Initial insomnia                                                                1
  Insomnia                                                                        3
  Abnormal behaviour                                                              1
  **Renal and urinary disorders**                                                 **5 (0.8)**
  Calculus urinary                                                                1
  Nephrolithiasis                                                                 1
  Renal impairment                                                                3
  **Respiratory, thoracic, and mediastinal disorders**                            **2 (0.32)**
  Cough                                                                           1
  Dyspnoea                                                                        1
  **Skin and subcutaneous tissue disorders**                                      **25 (4.01)**
  Dermatitis                                                                      1
  Drug eruption                                                                   5
  Erythema nodosum                                                                1
  Pruritus                                                                        2
  Rash                                                                            14
  Rash generalized                                                                1
  Seborrhoeic dermatitis                                                          1
  Facial wasting                                                                  1
  **Vascular disorders**                                                          **5 (0.80)**
  Hypertension                                                                    5

The terms are based on MedDRA version 13.1.

Two cases of children received Epzicom (aged less than 15 years); however, no ADRs were reported.

Ischaemic heart diseases
------------------------

Although the association of abacavir with myocardial infarction (MI) was previously reported,[@b12] no ischaemic heart disease (IHD) associated with abacavir sulfate (ABC) administration (including MI and angina pectoris) was reported (one MI and one angina pectoris case were reported as ABC non-related AE). In the post-marketing surveillance of Ziagen (abacavir sulfate 300 mg) conducted from September 1999 to September 2009 (enrollment of the last patients was March 2008), none of the 643 patients (1345.7 person-years) developed IHD including MI (unpublished data, submitted elsewhere). In the present surveys, no case of IHDs including MI was reported either. Note that 180 of the 624 had been involved in Ziagen post-marketing surveillance as well; therefore, when combining data from two surveys, no case of IHD was reported in total 1087 patients (2452.99 person-years).

Adverse drug reactions by background characteristics of the subjects
--------------------------------------------------------------------

The influence of the background characteristics of the patients on ADR was analysed. The analysis revealed statistically significant differences in the incidence of ADR depending on history of anti-HIV drug therapy, history of allergy, other complications and the number of anti-HIV drugs concomitantly used (Table [4](#tbl4){ref-type="table"}), and all of which were significant with multivariate analysis (Table [5](#tbl5){ref-type="table"}). Although effect of pre-existing hepatic dysfunction was one of the topics of special focus because ABC is eliminated primarily by hepatic metabolism, no association was observed between pre-existing hepatic dysfunction and the incidence of ADR (Table [4](#tbl4){ref-type="table"}).

###### 

The frequency of adverse drug reactions according to the characteristics of the subjects

  Factors                                                                No. of patients                           With ADRs   No. of ADR events   Incidence of ADR (%)   *χ*[‡](#tf4-2){ref-type="table-fn"} or Fisher\'s exact test (based on cases)   
  ---------------------------------------------------------------------- ----------------------------------------- ----------- ------------------- ---------------------- ------------------------------------------------------------------------------ -------------------------------------------------
  Overall                                                                624                                       202         325                 32.4                   --                                                                             
  Sex                                                                    Male                                      579         191                 311                    33.0                                                                           NS
                                                                         Female                                    45          11                  14                     24.4                                                                           
  Age                                                                    Child                                     2           0                   0                      0                                                                              NS
                                                                         Adult[†](#tf4-1){ref-type="table-fn"}     599         198                 320                    33.1                                                                           
                                                                         Elderly[‡](#tf4-2){ref-type="table-fn"}   23          4                   5                      17.4                                                                           
  Ethinic groups                                                         Japanese                                  589         191                 304                    32.4                                                                           NS
                                                                         Others                                    35          11                  21                     31.4                                                                           
  History of treatment with antiretrovirals                              Absent                                    213         83                  132                    39.0                                                                           *p* = 0.015[\*](#tf4-4){ref-type="table-fn"}
                                                                         Present                                   411         119                 193                    29.0                                                                           
  History of allergy                                                     Absent                                    322         80                  129                    24.8                                                                           *p* \<0.0001[\*\*](#tf4-5){ref-type="table-fn"}
                                                                         Present                                   210         92                  148                    43.8                                                                           
                                                                         Unknown                                   92          30                  48                     32.6                                                                           
  Complications                                                          Absent                                    158         39                  53                     24.7                                                                           *p* = 0.018[\*](#tf4-4){ref-type="table-fn"}
                                                                         Present                                   466         163                 272                    35.0                                                                           
  Renal impairment                                                       Absent                                    586         186                 299                    31.7                                                                           NS
                                                                         Present                                   38          16                  26                     42.1                                                                           
  Hepatic disorder                                                       Absent                                    461         142                 213                    30.8                                                                           NS
                                                                         Present                                   163         60                  112                    36.8                                                                           
  Haemophilia                                                            Absent                                    584         189                 300                    32.4                                                                           NS
                                                                         Present                                   40          13                  25                     32.5                                                                           
  Number of concomitant anti-HIV drugs[§](#tf4-3){ref-type="table-fn"}   1 drug                                    284         78                  126                    27.5                                                                           *p* = 0.019[\*](#tf4-4){ref-type="table-fn"}
                                                                         2 drugs                                   263         89                  131                    33.8                                                                           
                                                                         3 drugs                                   62          27                  46                     43.6                                                                           
                                                                         4 drugs ≤                                 15          8                   22                     53.3                                                                           
  CDC classification                                                     A                                         240         84                  141                    35.0                                                                           NS
                                                                         B                                         34          11                  17                     32.4                                                                           
                                                                         C                                         121         47                  73                     38.8                                                                           
                                                                         Unknown                                   228         60                  94                     26.3                                                                           

NS, no statistical significance.

≥15 to ≤64 years.

Elderly patients.

Total numbers throughout the observed periods.

*p* \< 0.05.

*p* \< 0.01.

###### 

The background characteristics that are associated with the frequency of ADR^†^

  Factors                                     Odds ratio   95% confidence interval
  ------------------------------------------- ------------ -------------------------
  History of treatment with antiretrovirals   0.52         0.36--0.76
  History of allergy                          2.01         1.40--2.88
  Complications                               1.80         1.15--2.81
  Number of concomitant anti-HIV drugs        1.36         1.10--1.69

For history of allergy, 'unknown' was regarded as 'absent'; for CDC classification, 'unknown' was regarded as 'category A'

The incidence of ADR in the group without history of anti-HIV drug therapy (treatment naïve \[TN\]) was 39.0% (83/213), which was significantly higher than those having history of anti-HIV drug therapy (treatment experienced \[TE\]) (29.0%, 119/411) (*p* \< 0.05). When analysed by system organ class, the incidence of 'skin and subcutaneous tissue disorders' was significantly higher in TN (9.39%, 20/213) than in TE (1.22%, 5/411) (*p* \< 0.0001), which was mainly driven by the larger number of cases developing rash in TN (13 cases) than in TE (one case). A possible explanation for these differences is that many of the TE patients had received component of Epzicom, namely Ziagen (abacavir) and/or Epivir (lamivudine) prior to Epzicom. The incidence of 'metabolism and nutrition disorders' such as hyperglycaemia, hypertriglycaeridaemia was higher among TN patients (data not shown), suggesting the possibility that in TE patients, these disorders had already been induced by anti-HIV drugs and were counted as complications at the start of Epzicom. The incidence of ADR was 43.8% (92/210) in the group having history of allergy, which was significantly higher than in those without history of allergy (24.8%, 80/322) (*p* \< 0.01), which seemed to have been mainly driven by 'rash' (13/210 vs 4/322, *p* = 0.004). The incidence of ADRs became higher as the number of anti-HIV drugs concomitantly used increased recording 27.5% (78/284), 33.8% (89/263), 43.5% (27/62) and 53.3% (8/15) when the number of concomitant anti-HIV drugs was one, two, three and four, respectively (*p* \< 0.05), suggesting the influence from multiple-drug-combined therapy.

Hypersensitivity
----------------

Onset of hypersensitivity reaction was investigated on the basis of the survey forms filled by the physicians, using the criteria in Table [1](#tbl1){ref-type="table"}. Four cases of survey-defined hypersensitivity were reported (Table [6](#tbl6){ref-type="table"}), with the incidence of 0.64% (4/624), all of whom were abacavir naïve patients. Therefore, when calculating the incidence limiting to the abacavir naïve patients, the incidence was 0.9% (4/445). Close association of HLA-B\*5701 with abacavir-induced hypersensitivity reaction has been described,[@b12]--[@b20] which rarely expressed in Japanese people.[@b21] Nevertheless, in the present survey, all of the patients who developed hypersensitivity were Japanese. The symptoms of hypersensitivity were 'rash', 'malaise + vomiting', 'fever + rash' and 'drug eruption' (one case each). All of these symptoms were non-serious and disappeared or improved.

###### 

Patients presented hypersensitivity

      Adverse reaction    Association     Severity      Outcome       Time to onset (days)   Sex      Age   Complications                                                                     Concomitant suspected products   Comment from physicians
  --- ------------------- --------------- ------------- ------------- ---------------------- -------- ----- --------------------------------------------------------------------------------- -------------------------------- --------------------------------------------------------------------------
  1   Rash                Associated      Not serious   Ameliorated   61                     Male     28    Factor IX deficiency, Hepatitis C, Atrial septal defect, Pulmonary hypertension   --                               
  2   Vomiting, Malaise   Not ruled out   Not serious   Recovered     152                    Female   32    Oesophageal candidiasis, Acute lymphocytic leukaemia                              --                               
  3   Rash, Pyrexia       Not ruled out   Not serious   Recovered     9                      Male     46    Hepatitis B                                                                       LPV/rtv                          Association with HIV infection, LPV/rtv and Epzicom cannot be ruled out.
  4   Drug eruption       Not ruled out   Not serious   Ameliorated   13                     Male     38    --                                                                                LPV/rtv                          Association with HIV infection, LPV/rtv and Epzicom cannot be ruled out.

ddI, didanosine; d4T, stavudine; AZT, zidovudine; NVP, nevirapine; 3TC, lamivudine; LPV/rtv, lopinavir/ritonavir; TDF, tenofovir disoproxil fumarate; EFV, efavirenz.

Duration of Epzicom treatment prior to onset of adverse drug reactions
----------------------------------------------------------------------

Among the 202 patients having developed ADR (323 reactions in total), the duration of Epzicom treatment before onset of ADR was known in 187 patients. After the start of Epzicom, ADR developed within 180 days in 63.9% (129/202), between 181 and 365 days (1 year) in 78.2% (158/202), and on Day 366 and later in 14.4% (29/202). The frequent ADRs occurred within 180 days were hyperlipidaemia (25 cases), rash (14 cases), blood bilirubin increased (14 cases), hypertriglyceridaemia (13 cases) and so on. The most frequent ADRs developed on Day 366 and later was hyperlipidaemia (15 cases).

Pregnant cases
--------------

Information on pregnant women was collected on one case during the survey period (with one newborn collected as well). In this case, non-serious 'aggravation of anaemia' (56 days after the start of Epzicom) and 'aggravation of nausea' (28 days after the start of Epzicom) developed during the course of pregnancy (Epzicom had been started 142 days before the delivery). The causal relationship to the product was not 'ruled out'. A normal baby was delivered at gestational age of 36 weeks by a caesarean section. Mild anaemia and transient tachypnea were reported in the neonate on the date of birth.

Effectiveness analysis
----------------------

Effectiveness analysis was performed on only TN patients whose HIV surrogate markers (plasma viral load and CD4 + T-cell count) at baseline and after the start of Epzicom were available. Among the TN patients who received therapy including Epzicom for 12 consecutive months, the percentages of patients with plasma HIV-RNA \<400 copies/mL and \<50 RNA copies/mL were 97.5% (130/134) and 74.6% (101/134), respectively. In addition, among the TN patients treated for 24 consecutive months, the percentages were 97.5% (74/76) and 73.7% (56/76), respectively ([Figure 1](#fig01){ref-type="fig"}a). When the patients were stratified according the baseline HIV-RNA level (cutoff level: 100 000 copies/mL), plasma viral load at 12 and 24 months was \<400 copies/mL in the majority cases, whereas the percentage of cases \<50 RNA copies/mL was lower regardless of the baseline viral load (\<100 000 RNA copies/mL, 77.8% \[12 months\], 80.0% \[24 months\]; \>100 000 RNA copies/mL, 70.5% \[12 months\], 61.5% \[24 months\]) ([Figure 1](#fig01){ref-type="fig"}b and [1](#fig01){ref-type="fig"}c). The mean CD4 + T lymphocyte count increased from 180/μL (baseline) to 444/μL after 24 months of the Epzicom treatment ([Figure 2](#fig02){ref-type="fig"}).

![Proportion of treatment-naïve subjects who achieved \<50 or \<400 HIV-RNA copies/mL after 12 and 24 months of treatment with ABC/3TC containing regimen. (a) All treatment-naïve HIV + subjects, (b) treatment-naïve subjects with baseline pVL \<100 000 RNA copies/mL, and (c) treatment-naïve subjects with baseline pVL \>100 000 RNA copies/mL. Note that the denominators are those who were on Epzicom treatment for the given duration, therefore not including those who stopped Epzicom earlier](pds0023-0372-f1){#fig01}

![Change in mean CD4 + T-cell count after initiation of ABC/3TC in treatment-naïve HIV + subjects. Mean absolute CD4 + T-cell count is shown in the solid line, and the vertical bars indicate standard deviation. Note that the number of subjects shown is those whose CD4+ T-cell count was available at each time point](pds0023-0372-f2){#fig02}

DISCUSSION
==========

On the basis of the 10-year post-marketing survey on Ziagen Tablet (abacavir sulfate 300 mg), we recently reported that the incidence of serious ADR associated with abacavir was 1.9% (12/643) and that no death occurred from the use of this drug, indicating abacavir can be used relatively safely for Japanese HIV-positive patients[@b22]. Lamivudine has been marketed for over 10 years in Japan and used not only for HIV infection but also for Hepatitis B virus infection,[@b23]--[@b25] showing superior tolerability. The present post-marketing surveillance on Epzicom Tablet (a combination of abacavir and lamivudine) in Japanese patients was expected to yield more useful information, particularly for abacavir.

The incidence of ADR reported in this survey was clearly lower than those in the post-marketing survey on Ziagen tablet. The most feasible explanation for this was because substantial part of the patients had received Ziagen (abacavir) or Epivir (lamivudine) before starting Epzicom, few of them presented new ADRs upon switching to Epzicom. A couple of other factors might have contributed to this finding, including 'trend toward early diagnosis and initiation of cART' before patients becoming sick. Likewise, improved safety profile of other anti-HIV drugs concomitantly used might have affected the findings.

A recent meta-analysis by the US FDA denied the possibility that abacavir is associated with MI.[@b26] However, this possibility is one of the major reasons why the combination abacavir/lamivudine has not been listed as a preferred NRTI backbone for TN patients in the DHHS Guidelines.[@b1] The incidence of IHD is known to be lower in Japanese people than in Western people,[@b27]--[@b29] yet the possibility of IHD is sometimes taken into account when physicians prescribe abacavir to Japanese patients. In the present survey, analysis of the data combined from post-marketing surveys on Ziagen Tablet[@b22] and Epzicom Tablet revealed no case developing IHD among 1087 patients treated with abacavir (2452.99 person-years). This result seems to serve as information useful in prescription of this product in Japanese population. However, regular pharmacovigilance activity is of paramount importance to monitor any signal for the risk of MI by this drug for patient safety.

In the post-marketing survey on Ziagen, 15 cases of hypersensitivity (2.3%) were reported, whereas the incidence of hypersensitivity was only 0.9% (4/445) in this Epzicom survey, which reassures that the risk of hypersensitivity to abacavir in Japanese population is substantially low; nevertheless, in view of the report on cases of suspected hypersensitivity among patients not expressing HLA-B\*5701,[@b13] it is necessary to monitor patients carefully when Epzicom is used.

Regarding effectiveness, because ACTG5202 Study demonstrated that abacavir/lamivudine (ABC/3TC) is inferior to tenofovir/emtricitabine (TDF/FTC) in patients with baseline virus load over 100 000 RNA copies/mL,[@b6] it has been one of the reason why the DHHS guideline does not list ABC/3TC as preferred NRTI backbone.[@b1] However, other studies reported no difference in effectiveness between the two arms.[@b5],[@b30],[@b31] In the present survey, TN patients with baseline plasma virus load over 100 000 copies/mL showed relatively good virological responses; however, we could not make any definite conclusion because it was non-controlled observational study designed for safety surveillance. Although data generation on effectiveness of ABC/3TC when used with modern powerful key drugs such as boosted darunavir or raltegravir has been evolving,[@b32],[@b33] evidence from controlled clinical trials should be generated for the fair evaluation for the effectiveness of Epzicom.

In conclusion, the present survey convinced abacavir and lamivudine can be used relatively safely in Japanese HIV-positive population. However, regular pharmacovigilance should be continued for patient safety.
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KEY POINTS
==========

-   Abacavir/lamivudine fixed-dose combination tablet can be well tolerated by Japanese HIV + people.

-   Hypersensitivity reaction to abacavir was observed in 0.9% of treatment-naive HIV + patients.

-   No case of myocardial infarction associated with abacavir administration was observed among 624 cases (1107.3 person-years).
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[^1]: The data presented in this study was officially reported to the Japanese regulatory authority (Phamaceuticals and Medical Devices Agency, PMDA) and is available at the following website: <http://www.info.pmda.go.jp/saishinsa/P201200044/16627200_22100AMX00411_A100_1.pdf>.
